How could 9 years
of cell and gene
therapy research
improve the patient
journey?
Let us show you how
How could 8 years of cell and gene
therapy research improve the patient
journey?
Let us show you how
EXUMA is a clinical-stage biotechnology company
developing gene vector delivery solutions and
products to improve patient access to innovation in
the cell and gene therapy space.
rPOC SC Platform
A dedicated synthetic lymph node as a CAR production line
EXUMA’s rPOC Subcutaneous (SC) platform has been designed to optimize efficacy and safety, while eliminating the need for lymphodepleting chemotherapy. rPOC SC autologous cell therapies have the potential for administration in settings away from tertiary care.
GCAR Platform
Reprograming your own lymph nodes
EXUMA is advancing the technology underpinning rPOC to enable in vivo CAR-T therapy.
Technologies
Addressing the Different Limitations of Cell Therapy
CD3-Targeted LV
EXUMA’s CD3-Targeted lentivector selectively targets and loads lymphocytes ex vivo or in vivo for subsequent transduction and all in vivo expansion
- Reduced manufacturing time, cost & complexity
FITNESS DRIVER
EXUMA’s FITNESS DRIVER transgene encodes a semi-synthetic protein identified for optimization of effector cell stemness, proliferation, persistence, and cytotoxicity with all in vivo expansion without the need for preparative lymphodepleting chemotherapy
- Enhanced efficacy & safety
- Expanded setting of care
Tumor Metabolism Regulated (TMR) CARs
EXUMA’s TMR CARs significantly expands the universe of targetable antigens beyond those unique to solid tumors
- Selective binding
Synthetic CAR Ligands (SCL)
EXUMA’s Synthetic CAR ligand enables expansion and persistence with administration of an off-the-shelf mRNA encoding a CAR activating ligand
- Designed to provide the physician control of PK
- Designed to enhance expansion & persistence
Pipeline
EXUMA Biotech is discovering and developing cell and gene therapies for autoimmune disease and cancer.
